METExon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations

This publication has 78 references indexed in Scilit:

• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
  Clinical Cancer Research, 2013
• MET As a Possible Target for Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2013
• Surgery for NSCLC in the era of personalized medicine
  Nature Reviews Clinical Oncology, 2013
• Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
  Journal of Clinical Oncology, 2009
• Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancer
  Cancer Science, 2008
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
  Proceedings of the National Academy of Sciences, 2007
• Determinants of RNA Quality from FFPE Samples
  PLOS ONE, 2007
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
  Science, 2007
• RNA expression analysis of formalin-fixed paraffin-embedded tumors
  Laboratory Investigation, 2007
• Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer
  Cancer Research, 2006